TP53 and malignant colon neoplasm: Current studies supported that AURKA was associated with the development of colorectal cancer by causing genomic instability [57], but high expression of AURKA in colon cancer enhanced the chemotherapy sensitivity of platinum drugs by inhibiting the expression of TP53-regulated DNA damage response genes, which may explain the corresponding better prognosis [56].